

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**REVOCATION OF POWER OF ATTORNEY, NEW POWER OF
ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


INTERMUNE INC., the owner of the entire right, title and interest in the U.S. patent applications and patents identified on the attached listing (Schedule A), hereby revokes all Powers of Attorney previously given in such patent applications and patents. INTERMUNE INC. is the Assignee of the entire right and interest in each of these U.S. patent applications and patents, as evidenced by the documentary evidence of the chain of title from the original owner to the Assignee, recorded in the Assignment records of the office at the reel/frame numbers indicated on Schedule A.

INTERMUNE INC. hereby appoints the attorneys and/or agents associated with customer number 89229 to prosecute these patent applications and patents and transact all business in the U.S. Patent and Trademark Office.

Please recognize and change the correspondence address for the patent applications and patents listed in Schedule A to the address associated with customer number 89229:

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive
Suite 6300
Chicago, Illinois 60606-6357
(312) 474-6300

INTERMUNE INC.


Name: John Bendrick
Title: Vice President, Intellectual Property, InterMune, Inc.
Date: March 31, 2010

Schedule A

U.S. Patents						
MGB Ref. Client Ref.	Application Number	Filing or 371(c) Date	Patent No.	Issue Date	Title	Reel/Frame
30481/30023	09/044,441	03/19/1998	5,962,478	10/5/1999	Inhibition of Tumor Necrosis Factor Alpha	022123/0967 (1/19/2009) 022331/0865 (3/4/2009)
L03103-US01CP						
30481/30023A	09/364,562	7/30/1999	6,300,349	10/9/2001	Inhibition of Tumor Necrosis Factor Alpha	022123/0967 (1/19/2009) 022331/0865 (3/4/2009)
L03103-US02CP						
30481/30024	09/162,011	9/28/1998	6,090,822	7/18/2000	Treatment of Cytokine Growth Factor Caused Disorders	022123/0967 (1/19/2009) 022331/0865 (3/4/2009)
L03102-US02CP						
30481/30026	09/239,211	1/28/1999	6,114,353	9/5/2000	Compositions and Method for Treatment of Lymphomas, Leukemias, and Leiomyomas	022123/0967 (1/19/2009) 022331/0865 (3/4/2009)
L03102-US03CP						
30481/30026A	09/724,378	1/28/1999	RE40155	3/18/2008	Methods for Treatment of Benign and Malignant Tumors, Including Lymphomas, Leukemias, and Leiomyomas	022123/0967 (1/19/2009) 022331/0865 (3/4/2009)
L03102-US03CP RE						
30481/30027	10/204,605	12/10/2002	6,956,044	10/18/2005	Compositions and Methods for Treatment of Epilepsy	022123/0967 (1/19/2009) 022331/0865 (3/4/2009)
L03104-US00WO						
30481/30028	07/947,995	9/21/1992	5,310,562	5/10/1994	Composition and Method for Reparation and Prevention of Fibrotic Lesions	016026/0534 (12/1/2004) 022123/0967 (1/19/2009) 022331/0865 (3/4/2009)
L03101-US02CB						

U.S. Patent Applications			
MGB Reference	Application No.	Filing Date	Title
30481/30025	09/563,063	4/24/2000	Compositions and Methods for Treatment of Malignant or Benign Tumor Disorders
L03105-US00NP			Reel/Frame 022123/0967 (1/19/2009) 022331/0865 (3/4/2009)